DNA-PK inhibitors

Patent metadata

Field	Value
Publication number	US-11008305-B2
Application number	US-201916538992-A
Country	US
Kind code	B2
Filing date	Aug 13, 2019
Priority date	Apr 24, 2012
Publication date	May 18, 2021
Grant date	May 18, 2021

Abstract

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

First claim

What is claimed is:

1. A method of potentiating a therapeutic regimen for the treatment of solid tumors/malignancies, myxoid and round cell carcinoma, locally advanced tumors, metastatic cancer, human soft tissue sarcomas, Ewing's sarcoma, cancer metastases, lymphatic metastases, squamous cell carcinoma, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, blood cell malignancies, multiple myeloma, leukemia, acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, hairy cell leukemia, effusion lymphomas, thymic lymphoma lung cancer, small cell carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cancer of the adrenal cortex, ACTH-producing tumors, non-small cell cancers, breast cancer, small cell carcinoma, ductal carcinoma, gastrointestinal cancer, stomach cancer, colon cancer, colorectal cancer, polyps associated with colorectal neoplasia, pancreatic cancer, liver cancer, urological cancer, bladder cancer, primary superficial bladder tumors, invasive transitional cell carcinoma of the bladder, muscle-invasive bladder cancer, prostate cancer, malignancies of the female genital tract, ovarian carcinoma, primary peritoneal epithelial neoplasms, cervical carcinoma, uterine endometrial cancer, vaginal cancer, cancer of the vulva, uterine cancer, solid tumors in the ovarian follicle, malignancies of the male genital tract, testicular cancer, penile cancer, kidney cancer, renal cell carcinoma, brain cancer, intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, glioma, metastatic tumor cell invasion in the central nervous system, bone cancer, osteoma, osteosarcoma, skin cancer, malignant melanoma, tumor progression of human skin keratinocytes, squamous cell cancer, thyroid cancer, retinoblastoma, neuroblastoma, peritoneal effusion, malignant pleural effusion, mesothelioma, Wilms's tumors, gall bladder cancer, trophoblastic neoplasms, hemangiopericytoma, or Kaposi's sarcoma in a patient comprising the step of administering to said patient an effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising said compound or pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the therapeutic regimen comprises radiation therapy or an anticancer chemotherapeutic agent; or both radiation therapy and an anticancer chemotherapeutic agent.

7. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is orally administered to the patient.

8. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is comprised in a capsule, tablet, or aqueous suspension.

9. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is comprised in a capsule.

10. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is comprised in a tablet.

11. A method of treating solid tumors/malignancies, myxoid and round cell carcinoma, locally advanced tumors, metastatic cancer, human soft tissue sarcomas, Ewing's sarcoma, cancer metastases, lymphatic metastases, squamous cell carcinoma, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, blood cell malignancies, multiple myeloma, leukemia, acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, hairy cell leukemia, effusion lymphomas, thymic lymphoma lung cancer, small cell carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cancer of the adrenal cortex, ACTH-producing tumors, non-small cell cancers, breast cancer, small cell carcinoma, ductal carcinoma, gastrointestinal cancer, stomach cancer, colon cancer, colorectal cancer, polyps associated with colorectal neoplasia, pancreatic cancer, liver cancer, urological cancer, bladder cancer, primary superficial bladder tumors, invasive transitional cell carcinoma of the bladder, muscle-invasive bladder cancer, prostate cancer, malignancies of the female genital tract, ovarian carcinoma, primary peritoneal epithelial neoplasms, cervical carcinoma, uterine endometrial cancer, vaginal cancer, cancer of the vulva, uterine cancer, solid tumors in the ovarian follicle, malignancies of the male genital tract, testicular cancer, penile cancer, kidney cancer, renal cell carcinoma, brain cancer, intrin

Assignees

• Vertex Pharma

Inventors

• Charifson Paul S
• Cottrell Kevin Michael
• Deng Hongbo
• Duffy John P
• Gao Huai
• Giroux Simon
• Green Jeremy
• Jackson Katrina Lee
• Kennedy Joseph M
• Lauffer David J
• Ledeboer Mark Willem
• Li Pan
• Maxwell John Patrick
• Morris Mark A
• Pierce Albert Charles
• Waal Nathan D
• Xu Jinwang

Classifications

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title

• C07D413/10

  linked by a carbon chain containing aromatic rings · CPC title